A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

NCT03555994 · Completed

Last updated 2026-05-28

This clinical trial tests the effect of the drug MEDI0382 on liver glycogen levels in adults who are overweight or obese and have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 51 people

Who can join Ages 18–99 · all sexes

Timeline Started 2018-05 · est. completion 2021-04

Where 3 sites · Netherlands, Sweden, United Kingdom

What this study is testing ClinicalTrials.gov NCT03555994 ↗

Description as written by the study sponsor.

A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM). Approximately 20 subjects will be enrolled in Part A and approximately 30 subjects in Part B.

Treatments tested

MEDI0382 Drug

MEDI0382 administered subcutaneously
Placebo Drug

Placebo administered subcutaneously
Liraglutide Drug

Liraglutide administered subcutaneously

Main thing measured	Change in Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 4 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of 28 Days of Treatment (Part A Only)
Sponsor	MedImmune LLC
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03555994 ↗